BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29611195)

  • 1. In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.
    Rigolin GM; Saccenti E; Guardalben E; Cavallari M; Formigaro L; Zagatti B; Visentin A; Mauro FR; Lista E; Bassi C; Lupini L; Quaglia FM; Urso A; Bardi MA; Bonaldi L; Volta E; Tammiso E; Ilari C; Cafforio L; Melandri A; Cavazzini F; Negrini M; Semenzato G; Trentin L; Foà R; Cuneo A
    Br J Haematol; 2018 Apr; 181(2):229-233. PubMed ID: 29611195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.
    Lin K; Farahani M; Yang Y; Johnson GG; Oates M; Atherton M; Douglas A; Kalakonda N; Pettitt AR
    Br J Haematol; 2014 Nov; 167(3):346-55. PubMed ID: 25040181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
    Rigolin GM; Formigaro L; Cavallari M; Quaglia FM; Lista E; Urso A; Guardalben E; Martinelli S; Saccenti E; Bassi C; Lupini L; Bardi MA; Volta E; Tammiso E; Melandri A; Negrini M; Cavazzini F; Cuneo A
    Oncotarget; 2017 Apr; 8(17):28008-28020. PubMed ID: 28427204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.
    Brander DM; Friedman DR; Volkheimer AD; Christensen DJ; Rassenti LZ; Kipps TJ; Guadalupe E; Chen Y; Zhang D; Wang X; Davis C; Owzar K; Weinberg JB
    Br J Haematol; 2019 Feb; 184(4):605-615. PubMed ID: 30443898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.
    Blanco G; Puiggros A; Baliakas P; Athanasiadou A; García-Malo M; Collado R; Xochelli A; Rodríguez-Rivera M; Ortega M; Calasanz MJ; Luño E; Vargas M; Grau J; Martínez-Laperche C; Valiente A; Cervera J; Anagnostopoulos A; Gimeno E; Abella E; Stalika E; Hernández-Rivas JM; Ortuño FJ; Robles D; Ferrer A; Ivars D; González M; Bosch F; Abrisqueta P; Stamatopoulos K; Espinet B
    Oncotarget; 2016 Dec; 7(49):80916-80924. PubMed ID: 27821812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia.
    Visentin A; Bonaldi L; Rigolin GM; Mauro FR; Martines A; Frezzato F; Imbergamo S; Scomazzon E; Pravato S; Bardi MA; Cavallari M; Volta E; Cavazzini F; Nanni M; Del Giudice I; Facco M; Guarini A; Semenzato G; Foà R; Cuneo A; Trentin L
    Br J Cancer; 2019 Jul; 121(2):150-156. PubMed ID: 31209327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation-induced cytidine deaminase mRNA levels in chronic lymphocytic leukemia.
    Hancer VS; Kose M; Diz-Kucukkaya R; Yavuz AS; Aktan M
    Leuk Lymphoma; 2011 Jan; 52(1):79-84. PubMed ID: 21133730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.
    Kruzova L; Schneiderova P; Holzerova M; Vatolikova M; Divoka M; Turcsanyi P; Urbanova R; Kudelka M; Radvansky M; Kriegova E; Papajik T; Urbankova H
    Leuk Res; 2019 Oct; 85():106218. PubMed ID: 31476701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
    Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
    Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Japanese B cell chronic lymphocytic leukaemia: a cytogenetic and molecular biological study.
    Asou H; Takechi M; Tanaka K; Tashiro S; Dohy H; Ohno R; Kamada N
    Br J Haematol; 1993 Nov; 85(3):492-7. PubMed ID: 8136271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.
    Juliusson G; Oscier DG; Fitchett M; Ross FM; Stockdill G; Mackie MJ; Parker AC; Castoldi GL; Guneo A; Knuutila S; Elonen E; Gahrton G
    N Engl J Med; 1990 Sep; 323(11):720-4. PubMed ID: 2201915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
    Pabst T; Peters UR; Tinguely M; Schwaller J; Tschan M; Aebi S; Vonlanthen S; Borisch B; Betticher DC; Zimmermann A; Tobler A; Fey MF
    Leuk Lymphoma; 2000 May; 37(5-6):639-48. PubMed ID: 11042528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
    Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
    Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of CD38 and ZAP70 mRNA expression among cytogenetic subgroups of Iranian chronic-lymphocytic-leukemia patients.
    Teimori H; Akbari MT; Hamid M; Forouzandeh M; Bibordi E
    Genet Mol Res; 2011 Oct; 10(4):2415-23. PubMed ID: 22002134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature.
    Jarošová M; Plevová K; Kotašková J; Doubek M; Pospíšilová Š
    Leuk Lymphoma; 2019 Oct; 60(10):2348-2355. PubMed ID: 30773964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive activation of NF-κB signaling by NOTCH1 mutations in chronic lymphocytic leukemia.
    Xu ZS; Zhang JS; Zhang JY; Wu SQ; Xiong DL; Chen HJ; Chen ZZ; Zhan R
    Oncol Rep; 2015 Apr; 33(4):1609-14. PubMed ID: 25633905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicobiologic importance of cytogenetic lesions in chronic lymphocytic leukemia.
    Cavazzini F; Ciccone M; Negrini M; Rigolin GM; Cuneo A
    Expert Rev Hematol; 2009 Jun; 2(3):305-14. PubMed ID: 21082972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LPL protein in Chronic Lymphocytic Leukaemia have different origins in Mutated and Unmutated patients. Advances for a new prognostic marker in CLL.
    Prieto D; Seija N; Uriepero A; Souto-Padron T; Oliver C; Irigoin V; Guillermo C; Navarrete MA; Inés Landoni A; Dighiero G; Gabus R; Giordano M; Oppezzo P
    Br J Haematol; 2018 Aug; 182(4):521-525. PubMed ID: 29953583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL.
    Kern W; Bacher U; Haferlach C; Dicker F; Alpermann T; Schnittger S; Haferlach T
    Br J Haematol; 2012 Apr; 157(1):86-96. PubMed ID: 22224978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Aoun P; Blair HE; Smith LM; Dave BJ; Lynch J; Weisenburger DD; Pavletic SZ; Sanger WG
    Leuk Lymphoma; 2004 Aug; 45(8):1595-603. PubMed ID: 15370211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.